Format

Send to

Choose Destination
Int J Med Sci. 2018 Aug 10;15(12):1334-1340. doi: 10.7150/ijms.27059. eCollection 2018.

Impact of ADAM10 gene polymorphisms on hepatocellular carcinoma development and clinical characteristics.

Shiu JS1, Hsieh MJ2,3,4, Chiou HL5,6, Wang HL7, Yeh CB8,9, Yang SF2,10, Chou YE8,10.

Author information

1
Department of Emergency Medicine, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan.
2
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
3
Cancer Research Center, Changhua Christian Hospital, Changhua, Taiwan.
4
Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
5
School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung, Taiwan.
6
Department of Clinical Laboratory, Chung Shan Medical University Hospital, Taichung, Taiwan.
7
Department of Beauty Science, National Taichung University of Science and Technology, Taichung, Taiwan.
8
School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
9
Department of Emergency Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
10
Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.

Abstract

A disintegrin and metalloprotease (ADAM) family proteins are type-I transmembrane glycoproteins with multiple functions in cell adhesion, migration, proteolysis and signaling. ADAM10 is a member of the ADAM family reportedly involved in cancer progression and has been shown to be overexpressed in hepatocellular carcinoma (HCC) tissues and significantly associated with tumor progression and shortened survival. This study investigated ADAM10's single nucleotide polymorphisms (SNPs) and their association to HCC development and regulation. Real-time polymerase chain reaction was used to analyze five SNPs of ADAM10 in 333 patients with HCC and 1196 controls without cancer. The results indicated that of the 333 patients with HCC, those who carried ADAM10 rs514049 (AC + CC) variants had a higher risk of developing lymph node metastasis (odds ratio [OR] = 5.087, p = 0.027), and those who carried ADAM10 rs653765 (GA + AA) variants had a higher risk of developing distant metastasis (OR = 3.346, p = 0.020) and higher levels of α-fetoprotein. In conclusion, our study demonstrated that the SNPs of ADAM10 are involved in HCC progression. ADAM10 SNPs may be used as therapeutic targets to evaluate poor prognoses for HCC.

KEYWORDS:

A disintegrin and metalloprotease 10; Hepatocellular carcinoma; polymorphism

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Supplemental Content

Full text links

Icon for Ivyspring International Publisher Icon for PubMed Central
Loading ...
Support Center